Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_47
Snippet: In summary, our model provides a broad platform for assessment of all major types of therapies. Our results demonstrate the need to differentiate whether duration of viral shedding or viral area under the curve is the more relevant surrogate of severity. If viral area under the curve is most predictive of poor outcomes, then all forms of antiviral therapy outside of potent post exposure prophylaxis are unlikely to provide clinical benefit. Howeve.....
Document: In summary, our model provides a broad platform for assessment of all major types of therapies. Our results demonstrate the need to differentiate whether duration of viral shedding or viral area under the curve is the more relevant surrogate of severity. If viral area under the curve is most predictive of poor outcomes, then all forms of antiviral therapy outside of potent post exposure prophylaxis are unlikely to provide clinical benefit. However, if shedding duration is the best surrogate, then an early test and treat approach is highly promising for limiting the likelihood of severe disease.
Search related documents:
Co phrase search for related documents- antiviral therapy and clinical benefit: 1, 2, 3, 4, 5, 6, 7
- antiviral therapy and curve viral area: 1
- antiviral therapy and early test: 1
- antiviral therapy and major type: 1
- antiviral therapy and poor outcome: 1, 2, 3
- antiviral therapy and post exposure: 1, 2, 3, 4, 5, 6, 7
- antiviral therapy and post exposure prophylaxis: 1, 2, 3, 4, 5
- antiviral therapy and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral therapy and viral area: 1
- antiviral therapy and viral shedding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- approach treat and clinical benefit: 1
- approach treat and curve viral area: 1
- approach treat and early test: 1
- approach treat and severe disease: 1, 2, 3, 4, 5
- approach treat and viral area: 1
- approach treat and viral shedding: 1
- clinical benefit and poor outcome: 1, 2, 3, 4, 5, 6
- clinical benefit and post exposure: 1, 2, 3, 4, 5
- clinical benefit and post exposure prophylaxis: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date